JCB, Volume 18, Number 1, 2012 Editorial Vol.18 No. 1 (2012) Exciting changes Yali Friedman Article Vol.18 No. 1 (2012) Bacterial proteins: A new class of cancer therapeutics Ananda Mohan Chakrabarty Cancer is a complex disease with a network of multiple metabolic pathways that are interlinked to promote growth and resist immune surveillance. Such a network is efficiently maintain Article Vol.18 No. 1 (2012) Industrial biotechnology – Markets and industry structure Gunter Festel Article Vol.18 No. 1 (2012) Options to change Medicare payment for outpatient prescription drugs and biotechnology products Thomas Barker The debates over the Obama Administration’s health care reform law, and, more recently, the federal budget deficit and national debt have focused attention on the growth in costs o Article Vol.18 No. 1 (2012) The emergence of bio-clusters in Egypt and South Africa Ramazan Uctu There is a wide body of literature on biotechnology clusters. However, most of the works has been focused on the description of the clusters as well as the development of biotechnology cl Article Vol.18 No. 1 (2012) Patent litigation in India and interim injunctions — An evolving jurisprudence Rajashree Sharma This paper attempts to summarize and analyze the judicial trend towards granting or denying interim injunctive relief in patent litigation arena. From the Classroom Vol.18 No. 1 (2012) The University of Colorado Certificate Program in Bioinnovation and Entrepreneurship: An interdisciplinary, cross-campus model Madhavan Parthasarathy From the Boardroom Vol.18 No. 1 (2012) Digital health investment opportunities abound, but standouts deliver disruptive change G. Steven Burrill The convergence of ubiquitous smartphones, wireless Internet, and low-cost monitoring devices, is driving the emergence of a new world of digital health. At the same time, cost pressures From the Boardroom Vol.18 No. 1 (2012) Strategies for collaboration agreements focusing on innovation Pamela Cox Collaborations focusing on innovation are often born with the conception of a technology, typically as a result of one side’s research effort. Collaborations for innovation can also b From the Boardroom Vol.18 No. 1 (2012) Biomarketing strategy and tactics 101 PART I of III Dimitris Dogramatzis The American Marketing Association defines marketing as the activity, set of institutions, and processes for creating, communicating, delivering, and exchanging offerings that have value for Legal and Regulatory Updates Vol.18 No. 1 (2012) EU Legal & Regulatory Update Ewan Grist Legal and Regulatory Updates Vol.18 No. 1 (2012) Post-Grant Review: The Good, the Bad and the Ugly for Biotechnology Companies Smitha Uthaman This paper summarizes the Post-Grant Review process, one of the many interesting aspects of patent reform brought about by the enactment of the America Invents Act, and the effect it may hav Book Review Vol.18 No. 1 (2012) Book Review: Constructing and Deconstructing Patents by Irah H. Donner David B. Orange  Book Review Vol.18 No. 1 (2012) Book Review: Plunkett's Biotech & Genetics Industry Almanac 2012 Barry J. Marenberg
